Clearmind Medicine (CMND) Competitors $0.95 0.00 (-0.45%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$0.95 +0.00 (+0.38%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMND vs. TRAW, SYBX, HOTH, EGRX, LIXT, FNCH, THAR, NXTC, FBLG, and EDSAShould you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include Traws Pharma (TRAW), Synlogic (SYBX), Hoth Therapeutics (HOTH), Eagle Pharmaceuticals (EGRX), Lixte Biotechnology (LIXT), Finch Therapeutics Group (FNCH), Tharimmune (THAR), NextCure (NXTC), FibroBiologics (FBLG), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Clearmind Medicine vs. Its Competitors Traws Pharma Synlogic Hoth Therapeutics Eagle Pharmaceuticals Lixte Biotechnology Finch Therapeutics Group Tharimmune NextCure FibroBiologics Edesa Biotech Traws Pharma (NASDAQ:TRAW) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Is TRAW or CMND more profitable? Traws Pharma has a net margin of 3,028.25% compared to Clearmind Medicine's net margin of 0.00%. Clearmind Medicine's return on equity of -173.87% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma3,028.25% -1,812.48% 512.72% Clearmind Medicine N/A -173.87%-70.55% Which has better valuation and earnings, TRAW or CMND? Clearmind Medicine has lower revenue, but higher earnings than Traws Pharma. Clearmind Medicine is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$2.90M6.95-$166.52M$88.830.03Clearmind MedicineN/AN/A-$5.26M-$0.76-1.25 Which has more risk & volatility, TRAW or CMND? Traws Pharma has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Do analysts prefer TRAW or CMND? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to TRAW or CMND? In the previous week, Traws Pharma had 5 more articles in the media than Clearmind Medicine. MarketBeat recorded 6 mentions for Traws Pharma and 1 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 1.89 beat Traws Pharma's score of 0.56 indicating that Clearmind Medicine is being referred to more favorably in the news media. Company Overall Sentiment Traws Pharma Positive Clearmind Medicine Very Positive Do insiders & institutionals believe in TRAW or CMND? 7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 14.0% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryTraws Pharma beats Clearmind Medicine on 9 of the 13 factors compared between the two stocks. Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMND vs. The Competition Export to ExcelMetricClearmind MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.20M$2.96B$6.12B$10.45BDividend YieldN/A57.77%5.73%4.78%P/E Ratio-1.2522.7985.3827.36Price / SalesN/A778.16602.69196.46Price / CashN/A172.6337.4661.86Price / Book1.305.5112.516.81Net Income-$5.26M$33.06M$3.32B$276.80M7 Day Performance-1.55%0.23%0.60%0.42%1 Month Performance-6.30%14.73%10.53%7.86%1 Year Performance-33.82%-1.42%74.30%41.24% Clearmind Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMNDClearmind Medicine1.3013 of 5 stars$0.95-0.5%N/A-40.5%$5.20MN/A-1.25N/APositive NewsTRAWTraws Pharma0.8245 of 5 stars$2.85-3.3%N/A-41.0%$20.44M$230K0.0317SYBXSynlogic0.7192 of 5 stars$1.71flatN/A+17.5%$20.01M$10K-21.3880HOTHHoth Therapeutics1.8217 of 5 stars$1.50-2.9%$4.50+201.0%+72.6%$19.82MN/A-1.404EGRXEagle Pharmaceuticals1.4161 of 5 stars$1.50flatN/AN/A$19.48M$257.55M0.00100News CoverageLIXTLixte Biotechnology0.426 of 5 stars$4.25-4.5%N/A+135.0%$19.42MN/A-3.304News CoverageFNCHFinch Therapeutics GroupN/A$12.00-0.9%N/A+0.8%$19.28MN/A-1.36190THARTharimmune2.4558 of 5 stars$3.15+0.8%$17.00+440.5%+64.6%$18.64MN/A-0.522NXTCNextCure4.4967 of 5 stars$6.75+0.4%$25.50+277.8%-59.5%$18.09MN/A-0.2690FBLGFibroBiologics2.5193 of 5 stars$0.43+2.4%$12.67+2,845.7%-83.6%$18.01MN/A-1.1910News CoverageEDSAEdesa Biotech3.034 of 5 stars$2.55+1.6%$5.00+96.0%-38.3%$17.96MN/A-1.9320News Coverage Related Companies and Tools Related Companies TRAW Competitors SYBX Competitors HOTH Competitors EGRX Competitors LIXT Competitors FNCH Competitors THAR Competitors NXTC Competitors FBLG Competitors EDSA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMND) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
